2‘‐deocycoformycin after failure of alpha‐interferon in hairy cell leukemia

Sylvain Durrleman, Jean L. Grem, Bruce D. Cheson

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Alpha‐interferon (IFN) and 2‘‐deoxycoformycin (dCF) both exhibit substantial activity in the treatment of hairy cell leukemia (HCL). Anecdotal reports have suggested that patients who failed IFN could achieve durable responses with dCF, although the frequency with which this was said to have occurred was unknown. We reviewed the available data on the responsiveness of HCL to dCF after IFN therapy by analyzing cases reported in the literature and those treated under the Special Exception mechanism of the National Cancer Institute, Division of Cancer Treatment. Of 60 such cases identified there were 22 (37%) “compete responses” and 22 (37%) “partial responses” for a total response rate of 74%. Responses appeared to be durable in many cases, lasting up to 2 years at the time of reporting. dCF is an active agent in HCL both as initial therapy and for the salvage of patints who have failed IFN. The relative activity of these two agents and the optimal strategies for their use are currently under investigation in ongoing clinical trials.

Original languageEnglish (US)
Pages (from-to)297-302
Number of pages6
JournalEuropean Journal of Haematology
Volume43
Issue number4
DOIs
StatePublished - Oct 1989

Fingerprint

Hairy Cell Leukemia
Salvage Therapy
National Cancer Institute (U.S.)
Therapeutics
Clinical Trials
Neoplasms

Keywords

  • deoxycoformycin
  • hairy cell leukemia
  • interferon

ASJC Scopus subject areas

  • Hematology

Cite this

2‘‐deocycoformycin after failure of alpha‐interferon in hairy cell leukemia. / Durrleman, Sylvain; Grem, Jean L.; Cheson, Bruce D.

In: European Journal of Haematology, Vol. 43, No. 4, 10.1989, p. 297-302.

Research output: Contribution to journalArticle

@article{56ad52c70cd6481ead0b862096c8ebfd,
title = "2‘‐deocycoformycin after failure of alpha‐interferon in hairy cell leukemia",
abstract = "Alpha‐interferon (IFN) and 2‘‐deoxycoformycin (dCF) both exhibit substantial activity in the treatment of hairy cell leukemia (HCL). Anecdotal reports have suggested that patients who failed IFN could achieve durable responses with dCF, although the frequency with which this was said to have occurred was unknown. We reviewed the available data on the responsiveness of HCL to dCF after IFN therapy by analyzing cases reported in the literature and those treated under the Special Exception mechanism of the National Cancer Institute, Division of Cancer Treatment. Of 60 such cases identified there were 22 (37{\%}) “compete responses” and 22 (37{\%}) “partial responses” for a total response rate of 74{\%}. Responses appeared to be durable in many cases, lasting up to 2 years at the time of reporting. dCF is an active agent in HCL both as initial therapy and for the salvage of patints who have failed IFN. The relative activity of these two agents and the optimal strategies for their use are currently under investigation in ongoing clinical trials.",
keywords = "deoxycoformycin, hairy cell leukemia, interferon",
author = "Sylvain Durrleman and Grem, {Jean L.} and Cheson, {Bruce D.}",
year = "1989",
month = "10",
doi = "10.1111/j.1600-0609.1989.tb00302.x",
language = "English (US)",
volume = "43",
pages = "297--302",
journal = "European Journal of Haematology",
issn = "0902-4441",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - 2‘‐deocycoformycin after failure of alpha‐interferon in hairy cell leukemia

AU - Durrleman, Sylvain

AU - Grem, Jean L.

AU - Cheson, Bruce D.

PY - 1989/10

Y1 - 1989/10

N2 - Alpha‐interferon (IFN) and 2‘‐deoxycoformycin (dCF) both exhibit substantial activity in the treatment of hairy cell leukemia (HCL). Anecdotal reports have suggested that patients who failed IFN could achieve durable responses with dCF, although the frequency with which this was said to have occurred was unknown. We reviewed the available data on the responsiveness of HCL to dCF after IFN therapy by analyzing cases reported in the literature and those treated under the Special Exception mechanism of the National Cancer Institute, Division of Cancer Treatment. Of 60 such cases identified there were 22 (37%) “compete responses” and 22 (37%) “partial responses” for a total response rate of 74%. Responses appeared to be durable in many cases, lasting up to 2 years at the time of reporting. dCF is an active agent in HCL both as initial therapy and for the salvage of patints who have failed IFN. The relative activity of these two agents and the optimal strategies for their use are currently under investigation in ongoing clinical trials.

AB - Alpha‐interferon (IFN) and 2‘‐deoxycoformycin (dCF) both exhibit substantial activity in the treatment of hairy cell leukemia (HCL). Anecdotal reports have suggested that patients who failed IFN could achieve durable responses with dCF, although the frequency with which this was said to have occurred was unknown. We reviewed the available data on the responsiveness of HCL to dCF after IFN therapy by analyzing cases reported in the literature and those treated under the Special Exception mechanism of the National Cancer Institute, Division of Cancer Treatment. Of 60 such cases identified there were 22 (37%) “compete responses” and 22 (37%) “partial responses” for a total response rate of 74%. Responses appeared to be durable in many cases, lasting up to 2 years at the time of reporting. dCF is an active agent in HCL both as initial therapy and for the salvage of patints who have failed IFN. The relative activity of these two agents and the optimal strategies for their use are currently under investigation in ongoing clinical trials.

KW - deoxycoformycin

KW - hairy cell leukemia

KW - interferon

UR - http://www.scopus.com/inward/record.url?scp=0024854233&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024854233&partnerID=8YFLogxK

U2 - 10.1111/j.1600-0609.1989.tb00302.x

DO - 10.1111/j.1600-0609.1989.tb00302.x

M3 - Article

C2 - 2583256

AN - SCOPUS:0024854233

VL - 43

SP - 297

EP - 302

JO - European Journal of Haematology

JF - European Journal of Haematology

SN - 0902-4441

IS - 4

ER -